FDA Approval and Description
EDARBYCLOR is a combination medication composed of azilsartan medoxomil and chlorthalidone. It was first FDA approved on December 20, 2011, for the treatment of high blood pressure. Azilsartan medoxomil acts as an angiotensin II receptor blocker, while chlorthalidone acts as a thiazide-like diuretic. This combination provides an effective treatment option for individuals with hypertension who may require a combination therapy to achieve blood pressure goals. The tablets are available for oral use and contain specific dosages of each active ingredient.
Alternative Medications
Aside from Edarbyclor, individuals with hypertension have alternative medication options available. One such alternative is Norvasc, which contains the generic version amlodipine. Norvasc functions as a dihydropyridine calcium channel blocker, providing a different mechanism of action compared to Edarbyclor. Switching to a different class of antihypertensive medication like Norvasc may help avoid unwanted side effects associated with Edarbyclor.
Generic Availability and Pricing
Edarbyclor does not have a lower-cost generic version available. The medication, which contains azilsartan medoxomil and chlorthalidone, is only available as a brand-name product. Without insurance, a 30-day supply of Edarbyclor can cost $272 at the average retail price. Patients should explore other treatment options if the cost of Edarbyclor is a concern.
Formulations and Dosage
Edarbyclor is available in tablet form and contains azilsartan medoxomil and chlorthalidone. The tablets are usually coated for immediate release, with specific dosages of the active ingredients. The standard dosages include combinations like 40 mg/12.5 mg and 40 mg/25 mg, which are prescribed based on the individual’s condition and response to the medication.
Drug Class and Usage
Edarbyclor belongs to the drug class known as Angiotensin II antagonists and diuretics. It is utilized in the treatment of high blood pressure, particularly in patients whose blood pressure requires control with multiple medications or as an initial therapy for those likely to need combination drug therapy to manage their condition effectively.
Side Effects and Interactions
The most common side effects of Edarbyclor include dizziness and tiredness. Other potential side effects may include signs of electrolyte imbalance such as dry mouth, extreme thirst, weakness, drowsiness, muscle pain or weakness, and fast heart rate. Interactions with other medications like arsenic trioxide may lead to an increased risk of hypokalemia and cardiac arrhythmias. It is important to consult a healthcare provider for a complete list of potential side effects and drug interactions.
Patient Assistance and Savings Programs
For patients prescribed Edarbyclor, there are various ways to save on the medication costs. One option is through manufacturer coupons that can reduce the out-of-pocket expenses. Additionally, patient assistance programs offered by pharmaceutical companies like Arbor Pharmaceuticals may provide financial assistance to eligible individuals who need help covering the cost of their prescription medications.
Legal Class and Availability
The FDA approved Edarbyclor in December 2011 for the treatment of hypertension in patients whose blood pressure has not been adequately controlled with one medication or as an initial therapy for patients likely to need multiple drugs to manage their condition effectively. It is available in 40/12.5-mg and 40/25-mg fixed-dose combinations.
Warnings and Contraindications
Edarbyclor should not be used in patients with a history of hypersensitivity to chlorthalidone or any component of the formulation. Cross-sensitivity with other thiazides or sulfonamides should be considered. Additionally, the medication is contraindicated in cases of anuria and renal decompensation. Due to potential fetal/neonatal morbidity and mortality, Edarbyclor should be discontinued as soon as pregnancy is detected.
Leave a Reply